SpringWorks Therapeutics Inc., a commercial-stage biopharmaceutical company, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use $(CHMP)$ has given a positive opinion recommending conditional marketing authorization for their drug, mirdametinib. This MEK inhibitor is intended for the treatment of symptomatic, inoperable plexiform neurofibromas in pediatric and adult patients with neurofibromatosis type 1 (NF1). The European Commission is expected to make a final decision in the third quarter of 2025. If approved, mirdametinib will become the first and only therapy in the European Union authorized for both adults and children with NF1-PN.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.